Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity

Title: Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity

Volume: 9 Issue: 7

Author(s): Ewa Lech-Maranda, Anna Korycka and Tadeusz Robak

Affiliation:

Keywords: Clofarabine, purine nucleoside analogues, mechanism of action, clinical application, acute leukemia

Abstract: Clofarabine is a second generation of purine nucleoside analogues designed to combine the most favorable pharmacokinetic properties of fludarabine and cladribine. Clofarabine acts by inhibiting DNA polymerases and ribonucleotide reductase as well as by inducing apoptosis in cycling and non-cycling cells. Phase I/II clinical studies revealed its efficacy in hematological malignancies, and in 2004 clofarabine was approved by the United States Food and Drug Administration for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia after at least two prior chemotherapy regimens. The mechanism of action, pharmacology and clinical activity of clofarabine is the subject of this review.

Cite this article as:

Lech-Maranda Ewa, Korycka Anna and Robak Tadeusz, Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity, Mini-Reviews in Medicinal Chemistry 2009; 9 (7) . https://dx.doi.org/10.2174/138955709788452586